Source: IPWatchdog.com

IPWatchdog.com argues that a series of US Supreme Court decisions, beginning in 2010 with cases like Bilski, Mayo, and Alice, has created significant uncertainty in patent eligibility law. The Court's rulings established that abstract ideas, laws of nature, and natural phenomena are not patentable but failed to provide clear guidance, leading to inconsistent applications by lower courts and patent examiners. This has made it nearly impossible for inventors and companies to predict whether their discoveries will qualify for patent protection.

The resulting legal confusion is harming American innovation by discouraging investment in high-risk, high-reward sectors. The article highlights a noticeable slowdown in venture capital for medical diagnostics, which a study estimates lost nearly $9.3 billion in funding in the years following the Mayo decision. This problem extends to fields like software, artificial intelligence, and pharmaceuticals, putting the United States at a competitive disadvantage against countries like China and those in Europe, which have clearer patent eligibility rules.

The author champions the bipartisan Patent Eligibility Restoration Act (PERA) as the solution. This proposed legislation would replace the current confusing judicial tests with clear statutory rules, largely restoring the previous legal framework. PERA would specify what remains ineligible for patents—such as unmodified genes and stand-alone mathematical formulas—while preserving essential requirements like novelty and non-obviousness. The article concludes that passing PERA is crucial to restoring investor confidence and ensuring America's continued leadership in technology and innovation.